Novartis Scraps Sale of Sandoz Assets to Aurobindo

Novartis AG said Thursday that it has canceled the divestment of the U.S. generic oral solids and dermatology businesses of its subsidiary Sandoz to Aurobindo Pharma USA Inc.
The Swiss drug maker said the decision was taken mutually after they didn’t receive approval for the deal from the U.S. Federal Trade Commission “within anticipated timelines.”
The Sandoz assets will continue to operate as part of Sandoz’s U.S. business, Novartis said.

https://www.marketscreener.com/NOVARTIS-9364983/news/Novartis-Scraps-Sale-of-Sandoz-Assets-to-Aurobindo-30293308/